News

The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which indicated that

The medication aims to reduce the volume of heterotopic ossification (HO) in these individuals and is administered orally at a recommended dose of 100mg once daily. Developed by

The preclinical T-cell engagers will be developed using Amberstone’s Tumor Microenvironment Activated ThErapeutics (T-MATE) platform. Henlius will select up to two targets under the agreement. The company will

This treatment is approved for use alongside diet and exercise to improve blood sugar control. Onswik is intended to provide steady basal insulin levels for seven days. The

The companies will integrate the Genialis Supermodel with Inventia’s RASTRUM 3D cell model platform to study pancreatic ductal adenocarcinoma (PDAC) and test therapeutic hypotheses. Initial findings from the

S32 led the oversubscribed financing round. Investors included Catalio Capital Management, European Tech Collective, and Firebrand River Capital. Other backers were Nvidia, PostScriptum, Redalpine, The Rockefeller Foundation, Singular,

The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net sales. The

Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related to commercialisation,

The company said programmes could be onboarded at the facility immediately, rather than after a construction and qualification period, with the site intended to support clinical and commercial